CN111560045A - Method for synthesizing lithocholic acid by taking BA as raw material - Google Patents
Method for synthesizing lithocholic acid by taking BA as raw material Download PDFInfo
- Publication number
- CN111560045A CN111560045A CN202010578080.4A CN202010578080A CN111560045A CN 111560045 A CN111560045 A CN 111560045A CN 202010578080 A CN202010578080 A CN 202010578080A CN 111560045 A CN111560045 A CN 111560045A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- reaction
- solvent
- lithocholic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 title claims abstract description 30
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000002994 raw material Substances 0.000 title claims abstract description 18
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 7
- 238000007239 Wittig reaction Methods 0.000 claims abstract description 21
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 14
- 238000006722 reduction reaction Methods 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- 239000012312 sodium hydride Substances 0.000 claims description 7
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 claims description 7
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 claims 1
- JFBRAUFNAQPWKO-UHFFFAOYSA-N ethyl 2-[methylidene(diphenyl)-$l^{5}-phosphanyl]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1P(=C)(C=1C=CC=CC=1)C1=CC=CC=C1 JFBRAUFNAQPWKO-UHFFFAOYSA-N 0.000 claims 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 238000007086 side reaction Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- ZNWOYQVXPIEQRC-ZRFCQXGJSA-N (8s,9s,10r,13s,14s,17r)-17-(1-hydroxypropan-2-yl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(CO)C)[C@@]1(C)CC2 ZNWOYQVXPIEQRC-ZRFCQXGJSA-N 0.000 description 2
- 102000001996 DNA Polymerase beta Human genes 0.000 description 2
- 108010001132 DNA Polymerase beta Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OPGYCKDTPNLLCZ-CHNGHHIASA-N OC[C@H]([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C.OCC([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C Chemical compound OC[C@H]([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C.OCC([C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=O)C OPGYCKDTPNLLCZ-CHNGHHIASA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种石胆酸的合成方法,采用21‑羟基‑20‑甲基孕甾‑4‑烯‑3‑酮(BA)为原料,经过氧化反应、Wittig反应、还原反应合成所述石胆酸。本发明石胆酸的合成方法,环境友好、步骤简单、副反应少、收率高,原料廉价易得,适用于工业化生产;解决了现有技术中合成成本高、收率低、不适合大规模工业化生产的问题。The invention discloses a method for synthesizing lithocholic acid, which adopts 21-hydroxy-20-methylpregna-4-ene-3-ketone (BA) as a raw material, and synthesizes the lithocholic acid through oxidation reaction, Wittig reaction and reduction reaction. Lithocholic acid. The method for synthesizing lithocholic acid of the invention has the advantages of environmental friendliness, simple steps, few side reactions, high yield, cheap and easy-to-obtain raw materials, and is suitable for industrial production; The problem of large-scale industrial production.
Description
技术领域technical field
本发明属于有机化学领域,具体涉及一种以21-羟基-20-甲基孕甾-4-烯-3-酮(BA)为原料合成石胆酸的方法。The invention belongs to the field of organic chemistry, in particular to a method for synthesizing lithocholic acid by using 21-hydroxy-20-methylpregna-4-en-3-one (BA) as a raw material.
背景技术Background technique
石胆酸(3α-羟基-5β-胆烷酸,式(4))是一种次级胆汁酸,别名又叫胆石酸,存在于高等脊椎动物胆汁中,其含量变化在肝脏病诊中具有重要的参考价值。石胆酸具有广泛的生物活性,如激活维生素D受体(J.Lipid Res.2005,46,46–57.)、抑制治疗糖尿病相关靶点PTP1B的活性(Bioorg.Med.Chem.Lett.2012,22,7237–7242)、激活治疗糖尿病的相关靶点TGR5受体(J.Med.Chem.2008,51,1831–1841)、抗菌和抗真菌(FarmacoSci.1984,39,305–315)、抗衰老活性(Int.J.Mol.Sci.2014,15,16522–16543)。特别是该化合物还具有抗肿瘤活性,近年来,发现石胆酸能抑制DNA聚合酶β的突变,降低因DNA聚合酶β突变而导致肿瘤出现的几率;2011年,由Concordia大学领导,同时包括来自麦吉尔大学、蒙特利尔犹太总医院戴维斯研究所及Saskatchewan大学的科学家在Oncotarget期刊上发表了:石胆酸可以选择性杀死数种类型的癌细胞,如那些发现于脑肿瘤和乳腺癌中的癌细胞,同时不影响正常细胞,预示着石胆酸用作化疗药物的巨大前景(Oncotarget2011,2,761-782)。Lithocholic acid (3α-hydroxy-5β-cholanoic acid, formula (4)) is a secondary bile acid, also known as cholelithic acid. important reference value. Lithocholic acid has a wide range of biological activities, such as activating vitamin D receptors (J. Lipid Res. 2005, 46, 46–57.), inhibiting the activity of PTP1B, a target related to the treatment of diabetes (Bioorg.Med.Chem.Lett.2012 , 22, 7237–7242), activation of TGR5 receptor, a relevant target for the treatment of diabetes (J.Med.Chem.2008,51,1831–1841), antibacterial and antifungal (FarmacoSci.1984,39,305–315), Anti-aging activity (Int. J. Mol. Sci. 2014, 15, 16522-16543). In particular, this compound also has anti-tumor activity. In recent years, it was found that lithocholic acid can inhibit the mutation of DNA polymerase β and reduce the probability of tumors arising from DNA polymerase β mutation; in 2011, led by Concordia University, including Lithocholic acid selectively kills several types of cancer cells, such as those found in brain tumors and breast cancer cancer cells, while not affecting normal cells, heralds great prospects for lithocholic acid as a chemotherapeutic agent (Oncotarget 2011, 2, 761-782).
Journal of Biological Chemistry,1946,162,555-563,报道用脱氧胆酸甲酯化后,用苯甲酰氯保护3位羟基,然后在用苯甲酰氯与7位羟基反应,然后依次进行碱性水解甲酯和3位上的苯甲酰基,甲酯化,高温热解脱水,碱性水解甲酯,氧化铂加氢反应,得到石胆酸。反应式如下:Journal of Biological Chemistry, 1946, 162, 555-563, reported that after methylation with deoxycholic acid, the 3-hydroxyl group was protected with benzoyl chloride, and then the 7-position hydroxy group was reacted with benzoyl chloride, followed by alkaline hydrolysis of the methyl ester. And the benzoyl group on the 3rd position, methyl esterification, high temperature pyrolysis dehydration, alkaline hydrolysis methyl ester, platinum oxide hydrogenation reaction to obtain lithocholic acid. The reaction formula is as follows:
此方法制备石胆酸过程中需要高温热解来脱掉苯甲酰基,路线繁琐,收率低,总收率只有23.5%,不适合用于大生产。In the process of preparing lithocholic acid by this method, high temperature pyrolysis is required to remove the benzoyl group, the route is cumbersome, the yield is low, and the total yield is only 23.5%, which is not suitable for large-scale production.
2016年,本发明课题组申请的专利(CN201610369086.4)中报道了以脱氧胆酸为原料,经过甲酯化保护、醋酐保护3位羟基、脱水、加氢、水解等反应合成石胆酸。反应式如下:In 2016, the patent (CN201610369086.4) applied by the research group of the present invention reported that deoxycholic acid was used as a raw material, and lithocholic acid was synthesized through reactions such as methylation protection, acetic anhydride protection of the 3-hydroxyl group, dehydration, hydrogenation, and hydrolysis. . The reaction formula is as follows:
虽然该方法原料易得、收率较高,总收率为76.3%,但是该路线仍比较长,在一定程度上限制了该路线的工业化应用。Although the raw materials are easy to obtain and the yield is high, the total yield is 76.3%, but the route is still relatively long, which limits the industrial application of the route to a certain extent.
目前已经报道的石胆酸合成路线不仅存在步骤过于繁琐、产率低、成本高等问题,而且以上报道的现有合成路线均以动物胆酸脱氧胆酸为起始原料,但由于禽流感、疯牛病、猪链球菌病和非洲猪瘟等疾病的出现,人们对于动物来源原料的安全性产生了怀疑,因此,研发一种基于植物源为原料,高效合成石胆酸的方法具有重要意义和工业化价值。The reported lithocholic acid synthetic route not only has the problems of too complicated steps, low yield and high cost, but also the existing synthetic routes reported above all use animal cholic acid deoxycholic acid as the starting material, but due to avian influenza, mad cow disease The emergence of diseases such as Streptococcus suis and African swine fever, people have doubts about the safety of animal-derived raw materials. Therefore, it is of great significance and industrial value to develop a method for the efficient synthesis of lithocholic acid based on plant sources. .
发明内容SUMMARY OF THE INVENTION
为了克服现有技术中存在的上述缺陷,本发明以21-羟基-20-甲基孕甾-4-烯-3-酮((20S)-21-hydroxy-20-methylpregn-4-en-3-one)为原料,经过氧化反应、Wittig反应、还原反应合成石胆酸LCA。本发明所述石胆酸的合成方法,步骤简单、环境友好、副反应少、收率可达到87.4%,原料廉价易得,适用于工业化生产。In order to overcome the above-mentioned defects in the prior art, the present invention uses 21-hydroxy-20-methylpregn-4-en-3-one ((20S)-21-hydroxy-20-methylpregn-4-en-3 -one) as the raw material, through oxidation reaction, Wittig reaction and reduction reaction to synthesize lithocholic acid LCA. The method for synthesizing lithocholic acid of the invention has the advantages of simple steps, environmental friendliness, few side reactions, a yield of 87.4%, cheap and easily available raw materials, and is suitable for industrial production.
本发明所使用的原料21-羟基-20-甲基孕甾-4-烯-3-酮((20S)-21-hydroxy-20-methylpregn-4-en-3-one)又称为BA(bisnoralcohol),来源于油脂工艺下脚料植物甾醇的发酵,是一种植物源的绿色原料,目前年产量达千吨级,价格便宜,能够很好避免现有技术中致病菌和病毒的感染问题。The raw material 21-hydroxy-20-methylpregn-4-en-3-one ((20S)-21-hydroxy-20-methylpregn-4-en-3-one) used in the present invention is also called BA ( bisnoralcohol), derived from the fermentation of phytosterols from oil and fat process wastes, is a green raw material of plant origin, with an annual output of 1,000 tons and low price, which can well avoid the infection problems of pathogenic bacteria and viruses in the prior art. .
本发明提供的以21-羟基-20-甲基孕甾-4-烯-3-酮(BA)原料合成石胆酸的方法,包括以下步骤:The method for synthesizing lithocholic acid with 21-hydroxy-20-methylpregna-4-en-3-one (BA) raw material provided by the invention comprises the following steps:
步骤(a):在第一溶剂中,式(1)所示的BA经氧化反应,得到式(2)化合物;Step (a): in the first solvent, the BA represented by the formula (1) undergoes oxidation reaction to obtain the compound of the formula (2);
步骤(b):在第二溶剂中,式(2)化合物经Wittig反应,得到式(3)化合物;Step (b): in the second solvent, the compound of formula (2) is subjected to Wittig reaction to obtain the compound of formula (3);
步骤(c):在第三溶剂中,式(3)化合物经还原反应,得到式(4)化合物石胆酸;Step (c): in the third solvent, the compound of formula (3) is subjected to reduction reaction to obtain the compound of formula (4) lithocholic acid;
所述反应过程如下反应式(i)所示:Described reaction process is shown in following reaction formula (i):
本发明步骤(a)中,所述氧化反应具体为:在第一溶剂中,式(1)所示的BA、TEMP O(2,2,6,6-四甲基哌啶氧化物)、碳酸氢钠、四丁基溴化铵、氧化剂发生氧化反应,得到式(2)化合物。In step (a) of the present invention, the oxidation reaction is specifically: in the first solvent, BA represented by formula (1), TEMP O (2,2,6,6-tetramethylpiperidine oxide), Sodium bicarbonate, tetrabutylammonium bromide and oxidant undergo oxidation reaction to obtain the compound of formula (2).
步骤(a)中,所述氧化反应在氧化剂的作用下进行,所述氧化剂选自N-氯代琥珀酰亚胺(NCS)、N-溴代琥珀酰亚胺(NBS)、2-碘酰基苯甲酸(IBX)等中的一种或多种;优选地,为N-氯代琥珀酰亚胺(NCS)。In step (a), the oxidation reaction is carried out under the action of an oxidizing agent, and the oxidizing agent is selected from N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), 2-iodoacyl One or more of benzoic acid (IBX) and the like; preferably, N-chlorosuccinimide (NCS).
步骤(a)中,式(1)所示的BA、TEMPO、碳酸氢钠、四丁基溴化铵、氧化剂的摩尔比为1:(0~1):(0~20):(0~1):(1~5);优选地,为1:(0.01~1):(1.35~20):(0.1~1):(1.15~5);进一步优选地,为1:0.01:1.35:0.1:1.15。In step (a), the molar ratio of BA, TEMPO, sodium bicarbonate, tetrabutylammonium bromide, and oxidant represented by formula (1) is 1:(0~1):(0~20):(0~1). 1): (1-5); preferably, 1: (0.01-1): (1.35-20): (0.1-1): (1.15-5); more preferably, 1: 0.01: 1.35: 0.1:1.15.
步骤(a)中,所述第一溶剂选自二氯甲烷、四氢呋喃、甲苯、二甲基亚砜、水等中的一种或多种;优选地,为二氯甲烷和水的混合溶剂。In step (a), the first solvent is selected from one or more of dichloromethane, tetrahydrofuran, toluene, dimethyl sulfoxide, water, etc.; preferably, it is a mixed solvent of dichloromethane and water.
步骤(a)中,所述氧化反应的温度为0~30℃;优选地,为0℃。In step (a), the temperature of the oxidation reaction is 0-30°C; preferably, it is 0°C.
步骤(a)中,所述氧化反应的时间为2~8h;优选地,为5h。In step (a), the oxidation reaction time is 2-8h; preferably, it is 5h.
在一具体实施方式中,式(2)化合物的合成步骤包括:式(1)所示的BA溶解在第一溶剂中,然后加入TEMPO、碳酸氢钠、四丁基溴化铵、NCS,发生氧化反应,得到式(2)化合物。In a specific embodiment, the synthesis step of the compound of formula (2) includes: BA represented by formula (1) is dissolved in the first solvent, then TEMPO, sodium bicarbonate, tetrabutylammonium bromide, NCS are added to generate Oxidation reaction yields the compound of formula (2).
步骤(b)中,所述Wittig反应具体为:在第二溶剂中,式(2)化合物、乙氧甲酰基亚甲基三苯基膦发生Wittig反应,得到式(3)化合物。In step (b), the Wittig reaction is specifically as follows: in the second solvent, the compound of formula (2) and ethoxyformylmethylene triphenylphosphine undergo Wittig reaction to obtain the compound of formula (3).
其中,式(2)化合物、乙氧甲酰基亚甲基三苯基膦的摩尔比为1:(1~5);优选地,为1:2。Wherein, the molar ratio of the compound of formula (2) to ethoxyformylmethylenetriphenylphosphine is 1:(1-5); preferably, it is 1:2.
其中,所述第二溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷等中的一种或多种;优选地,为甲苯。Wherein, the second solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, it is toluene.
其中,所述Wittig反应的温度为80~130℃;优选地,为110℃。Wherein, the temperature of the Wittig reaction is 80-130°C; preferably, it is 110°C.
其中,所述Wittig反应的时间为2~8h;优选地,为4h。Wherein, the time of the Wittig reaction is 2~8h; preferably, it is 4h.
或,步骤(b)中,所述Wittig反应具体为:在第二溶剂中,式(2)化合物、氢化钠、膦酰基乙酸三乙酯发生Wittig反应,得到式(3)化合物。Or, in step (b), the Wittig reaction is specifically: in the second solvent, the compound of formula (2), sodium hydride and triethyl phosphonoacetate undergo Wittig reaction to obtain the compound of formula (3).
其中,所述第二溶剂选自苯、甲苯、乙酸乙酯、四氢呋喃、己烷等中的一种或多种;优选地,为四氢呋喃。Wherein, the second solvent is selected from one or more of benzene, toluene, ethyl acetate, tetrahydrofuran, hexane, etc.; preferably, it is tetrahydrofuran.
其中,式(2)化合物、氢化钠、膦酰基乙酸三乙酯的摩尔比为1:(1~5):(1~5);优选地,为1:1.5:1.5。Wherein, the molar ratio of the compound of formula (2), sodium hydride and triethyl phosphonoacetate is 1:(1-5):(1-5); preferably, it is 1:1.5:1.5.
其中,所述Wittig反应的温度为0~30℃;优选地,为0℃。Wherein, the temperature of the Wittig reaction is 0-30°C; preferably, it is 0°C.
其中,所述Wittig反应的时间为2~8h;优选地,为4h。Wherein, the time of the Wittig reaction is 2~8h; preferably, it is 4h.
在一具体实施方式中,式(3)化合物的合成步骤包括:式(2)化合物、乙氧甲酰基亚甲基三苯基膦或式(2)化合物、氢化钠、膦酰基乙酸三乙酯溶解在第二溶剂中,发生Wittig反应,得到式(3)化合物。In a specific embodiment, the synthesis step of the compound of formula (3) comprises: compound of formula (2), ethoxyformylmethylene triphenylphosphine or compound of formula (2), sodium hydride, triethyl phosphonoacetate Dissolved in the second solvent, the Wittig reaction takes place to give the compound of formula (3).
步骤(c)中,所述还原反应具体为:式(3)化合物、叔丁醇钠、雷尼镍(RaneyNi)溶解在第三溶剂中,H2置换后加压,发生还原反应,得到式(4)化合物石胆酸;In step (c), the reduction reaction is specifically as follows: the compound of formula (3), sodium tert-butoxide, and RaneyNi (RaneyNi) are dissolved in the third solvent, and the H 2 is replaced and pressurized, and a reduction reaction occurs to obtain the formula (4) the compound lithocholic acid;
其中,式(3)化合物、叔丁醇钠的摩尔比为1:(1~5);优选地,为1:2。Wherein, the molar ratio of the compound of formula (3) and sodium tert-butoxide is 1:(1-5); preferably, it is 1:2.
其中,式(3)化合物、雷尼镍的质量比为1:(0.1~5);优选地,为1:1。Wherein, the mass ratio of the compound of formula (3) to Raney nickel is 1:(0.1-5); preferably, it is 1:1.
其中,所述第三溶剂选自异丙醇、正丁醇、乙醇、甲醇、叔丁醇等中的一种或多种;优选地,为异丙醇。Wherein, the third solvent is selected from one or more of isopropanol, n-butanol, ethanol, methanol, tert-butanol, etc.; preferably, it is isopropanol.
其中,所述还原反应的压强为1~10MPa;优选地,为4MPa。Wherein, the pressure of the reduction reaction is 1-10 MPa; preferably, it is 4 MPa.
其中,所述还原反应的温度为40~120℃;优选地,为90℃。Wherein, the temperature of the reduction reaction is 40-120°C; preferably, it is 90°C.
其中,所述还原反应的时间为5~48h;优选地,为24h。Wherein, the time of the reduction reaction is 5-48h; preferably, it is 24h.
本发明的有益效果包括,本发明石胆酸的制备方法,所用原料BA为植物源原料,避免了致病菌和病毒的感染问题,廉价易得;该石胆酸的合成步骤操作简便、副反应少、收率高87.4%,对环境友好,方便实现工业化和产业化生产;解决了现有技术中合成成本高、收率低、不适合大规模工业化生产的问题。The beneficial effects of the present invention include: the preparation method of lithocholic acid of the present invention uses raw material BA as a plant source material, which avoids the infection problem of pathogenic bacteria and viruses, and is cheap and easy to obtain; the synthesis steps of the lithocholic acid are simple and easy to operate. It has few reactions and high yield of 87.4%, is environmentally friendly, and is convenient to realize industrialization and industrialized production; it solves the problems of high synthesis cost, low yield and unsuitable for large-scale industrialized production in the prior art.
具体实施方式Detailed ways
结合以下具体实施例,对本发明作进一步的详细说明。实施本发明的过程、条件、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。The present invention will be further described in detail with reference to the following specific embodiments. Except for the content specifically mentioned below, the process, conditions, experimental methods, etc. for implementing the present invention are all common knowledge and common knowledge in the field, and the present invention is not particularly limited.
下述实施例中,化合物结构由核磁共振仪测定;试剂主要由上海国药化学试剂公司提供;产品纯化主要通过柱色谱,硅胶(200-300)由青岛海洋化工厂生产。In the following examples, the structure of the compounds was determined by nuclear magnetic resonance; the reagents were mainly provided by Shanghai Sinopharm Chemical Reagent Company; the products were purified mainly by column chromatography, and silica gel (200-300) was produced by Qingdao Ocean Chemical Factory.
实施例一式(2)化合物的制备Example 1 Preparation of compound of formula (2)
(1-1)于500mL单口烧瓶中依次加入BA(10.00g,30.26mmol)、TEMPO(47mg,0.30mmol)、100mL DCM、NaHCO3(3.43g,40.85mmol)、四丁基溴化铵(977mg,3.03mmol)的H2O(40mL)溶液和NCS(4.65g,34.80mmol),0℃下反应5h。TLC检测原料反应完全后,加入五水合硫代硫酸钠溶液(1.3g五水合硫代硫酸钠/25mL H2O),10℃下搅拌20min,分液,水相用二氯甲烷(50mL×3)萃取,合并有机相,加120mL 1%氢氧化钠溶液,搅拌30min,分液,水相用二氯甲烷(50mL)反萃一次,水洗,减压浓缩,得到化合物2(淡黄色固体,9.50g,摩尔收率95%)。(1-1) BA (10.00 g, 30.26 mmol), TEMPO (47 mg, 0.30 mmol), 100 mL DCM, NaHCO 3 (3.43 g, 40.85 mmol), tetrabutylammonium bromide (977 mg) were sequentially added to a 500 mL single-necked flask , 3.03 mmol) of H 2 O (40 mL) solution and NCS (4.65 g, 34.80 mmol) were reacted at 0 °C for 5 h. After TLC detected that the reaction of the raw materials was complete, sodium thiosulfate pentahydrate solution (1.3 g sodium thiosulfate pentahydrate/25 mL H 2 O) was added, stirred at 10° C. for 20 min, and the liquid was separated. The aqueous phase was washed with dichloromethane (50 mL×3 ) extraction, the organic phases were combined, 120 mL of 1% sodium hydroxide solution was added, stirred for 30 min, the layers were separated, the aqueous phase was back-extracted once with dichloromethane (50 mL), washed with water, and concentrated under reduced pressure to obtain compound 2 (pale yellow solid, 9.50 g, molar yield 95%).
(1-2)于250mL单口烧瓶中依次加入BA(5.0g,15.13mmol),IBX(8.5g,30.26mmol),50mL THF和50mL DMSO,室温反应5h。TLC检测反应完毕后加入水,抽滤,二氯甲烷(50mL×3)萃取,水(50mL×2)洗,饱和碳酸氢钠溶液(50mL)洗,无水硫酸钠干燥,减压浓缩,硅胶柱层析(PE/EA=3/1,v/v)纯化,得到化合物2(4.9g,白色固体,摩尔收率98%)。mp:155-157℃.1H NMR(400MHz,CDCl3)δ9.55(s,1H),5.71(s,1H),2.45-2.23(m,5H),1.99(t,J=13.7Hz,2H),1.91-1.78(m,2H),1.68(t,J=10.2Hz,2H),1.43(m,5H),1.30-1.19(m,2H),1.17(s,3H),1.11(d,J=5.5Hz,3H),1.06-0.89(m,3H),0.75(s,3H).13C NMR(100MHz,CDCl3)δ205.00,199.65,171.31,123.99,55.25,53.84,51.04,49.54,43.10,39.39,38.68,35.80,35.68,34.06,32.93,32.05,27.11,24.64,21.06,17.48,13.53,12.44.HRMS(ESI):calcdfor C22H32NaO2[M+Na]+,351.2295,found351.2292.(1-2) BA (5.0 g, 15.13 mmol), IBX (8.5 g, 30.26 mmol), 50 mL of THF and 50 mL of DMSO were sequentially added to a 250 mL single-necked flask, and reacted at room temperature for 5 h. After the reaction was detected by TLC, water was added, filtered with suction, extracted with dichloromethane (50 mL×3), washed with water (50 mL×2), washed with saturated sodium bicarbonate solution (50 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, silica gel Purification by column chromatography (PE/EA=3/1, v/v) gave compound 2 (4.9 g, white solid, 98% molar yield). mp: 155-157°C. 1 H NMR (400 MHz, CDCl 3 ) δ 9.55 (s, 1H), 5.71 (s, 1H), 2.45-2.23 (m, 5H), 1.99 (t, J=13.7 Hz, 2H), 1.91-1.78(m, 2H), 1.68(t, J=10.2Hz, 2H), 1.43(m, 5H), 1.30-1.19(m, 2H), 1.17(s, 3H), 1.11(d , J=5.5Hz, 3H), 1.06-0.89(m, 3H), 0.75(s, 3H). 13 C NMR (100MHz, CDCl 3 )δ205.00, 199.65, 171.31, 123.99, 55.25, 53.84, 51.04, 49.54, 43.10,39.39,38.68,35.80,35.68,34.06,32.93,32.05,27.11,24.64,21.06,17.48,13.53,12.44.HRMS(ESI):calcdfor C 22 H 32 NaO 2 [M+Na] + ,351.2295,found351 .2292.
实施例二式(3)化合物的制备The preparation of the compound of the second formula (3)
(2-1)于100mL单口烧瓶中依次加入化合物2(1.0g,3.04mmol),乙氧甲酰基亚甲基三苯基膦(2.12g,6.08mmol)和甲苯(15mL),回流反应4h。TLC检测反应完全后减压浓缩,硅胶柱层析(PE/EA=3/1,v/v)纯化,得到化合物3(1.15g,白色固体,摩尔收率98%)。(2-1) Compound 2 (1.0 g, 3.04 mmol), ethoxyformylmethylene triphenylphosphine (2.12 g, 6.08 mmol) and toluene (15 mL) were sequentially added to a 100 mL single-necked flask, and the reaction was refluxed for 4 h. TLC detected the completion of the reaction, concentrated under reduced pressure, and purified by silica gel column chromatography (PE/EA=3/1, v/v) to obtain compound 3 (1.15 g, white solid, molar yield 98%).
(2-2)于250mL单口烧瓶中依次加入氢化钠(913mg,22.83mmol)和50mLTHF,搅拌15min后依次加入膦酰基乙酸三乙酯(4.5mL,22.83mmol),化合物2(5.00g,15.22mmol),0℃下反应4h。TLC检测原料反应完全后,减压浓缩,甲醇打浆,得到化合物3(白色固体,5.76g,摩尔收率95%)。(2-2) Sodium hydride (913 mg, 22.83 mmol) and 50 mL of THF were successively added to a 250 mL single-necked flask, and after stirring for 15 min, triethyl phosphonoacetate (4.5 mL, 22.83 mmol), compound 2 (5.00 g, 15.22 mmol) were successively added. ) and reacted at 0 °C for 4 h. After TLC detected that the reaction of the raw materials was complete, the mixture was concentrated under reduced pressure and slurried with methanol to obtain compound 3 (white solid, 5.76 g, molar yield 95%).
(2-3)于100mL单口烧瓶中依次加入化合物2(1.0g,3.04mmol),乙氧甲酰基亚甲基三苯基膦(2.12g,6.08mmol)和THF(15mL),回流反应4h。TLC检测反应完全后减压浓缩,硅胶柱层析(PE/EA=3/1,v/v)纯化,得到化合物3(1.10g,白色固体,摩尔收率94%)。(2-3) Compound 2 (1.0 g, 3.04 mmol), ethoxyformylmethylene triphenylphosphine (2.12 g, 6.08 mmol) and THF (15 mL) were sequentially added to a 100 mL single-necked flask, and the reaction was refluxed for 4 h. TLC detected the completion of the reaction, concentrated under reduced pressure, and purified by silica gel column chromatography (PE/EA=3/1, v/v) to obtain compound 3 (1.10 g, white solid, molar yield 94%).
(2-4)于250mL单口烧瓶中依次加入氢化钠(913mg,22.83mmol)和50mL甲苯,搅拌15min后依次加入膦酰基乙酸三乙酯(4.5mL,22.83mmol),化合物2(5.00g,15.22mmol),0℃下反应4h。TLC检测原料反应完全后,减压浓缩,甲醇打浆,得到化合物3(白色固体,5.64g,摩尔收率93%)。mp:160-162℃.1H NMR(400MHz,CDCl3)δ6.81(dd,J=15.3,9.0Hz,1H),5.71(d,J=13.4Hz,2H),4.24-4.09(m,2H),2.45-2.21(m,5H),2.00(d,J=12.6Hz,2H),1.80(m,1H),1.76-1.33(m,7H),1.26(m,6H),1.17(s,3H),1.08(d,J=6.2Hz,3H),1.05-0.86(m,3H),0.73(s,3H).13C NMR(100MHz,CDCl3)δ199.70,171.51,167.16,154.56,123.94,119.21,60.27,55.78,54.98,53.84,42.82,39.80,39.54,38.69,35.80,35.70,34.08,32.98,32.06,28.19,24.28,21.10,19.31,17.49,14.40,12.32.HRMS(ESI):calcd forC26H38NaO3[M+Na]+,421.2713,found421.2708.(2-4) Sodium hydride (913 mg, 22.83 mmol) and 50 mL of toluene were successively added to a 250 mL single-necked flask, and after stirring for 15 min, triethyl phosphonoacetate (4.5 mL, 22.83 mmol) was added successively, compound 2 (5.00 g, 15.22 mmol), and reacted at 0 °C for 4 h. After TLC detected the reaction of the raw materials, the mixture was concentrated under reduced pressure and slurried with methanol to obtain compound 3 (white solid, 5.64 g, 93% molar yield). mp: 160-162°C. 1 H NMR (400 MHz, CDCl 3 ) δ 6.81 (dd, J=15.3, 9.0 Hz, 1H), 5.71 (d, J=13.4 Hz, 2H), 4.24-4.09 (m, 2H), 2.45-2.21(m, 5H), 2.00(d, J=12.6Hz, 2H), 1.80(m, 1H), 1.76-1.33(m, 7H), 1.26(m, 6H), 1.17(s , 3H), 1.08(d, J=6.2Hz, 3H), 1.05-0.86(m, 3H), 0.73(s, 3H). 13 C NMR (100MHz, CDCl 3 )δ199.70, 171.51, 167.16, 154.56, 123.94 HRMS calc 26 H 38 NaO 3 [M+Na] + , 421.2713, found421.2708.
实施例三式(4)化合物的制备The preparation of the compound of embodiment three formula (4)
(3-1)于高压反应釜中依次加入化合物3(1.0g,2.51mmol),20mL异丙醇,1.0gRaney Ni,H2(4.0MPa),叔丁醇钠(482mg,5.02mmol),90℃下反应48小时。TLC检测反应完全后加乙酸调pH至5,硅藻土抽滤,滤液减压浓缩后用乙酸乙酯(30mL)溶解,依次用水、饱和氯化钠溶液洗,无水硫酸钠干燥,减压浓缩,柱层析(PE:EA=2:1),得到石胆酸(841mg,白色固体,摩尔收率89%)。(3-1) Compound 3 (1.0g, 2.51mmol), 20mL isopropanol, 1.0g Raney Ni, H 2 (4.0MPa), sodium tert-butoxide (482mg, 5.02mmol), 90 mL were successively added to the autoclave. The reaction was carried out at °C for 48 hours. After TLC detected the completion of the reaction, acetic acid was added to adjust the pH to 5, and celite was suction filtered. The filtrate was concentrated under reduced pressure, dissolved in ethyl acetate (30 mL), washed with water and saturated sodium chloride solution in turn, dried over anhydrous sodium sulfate, and dried under reduced pressure. Concentration and column chromatography (PE:EA=2:1) gave lithocholic acid (841 mg, white solid, 89% molar yield).
(3-2)于高压反应釜中依次加入化合物3(1.0g,2.51mmol)、20mL异丙醇、叔丁醇钠(482mg,5.02mmol)和1.0g Raney Ni,H2置换后加压至4.0MPa,90℃下反应24h。TLC检测原料反应完全后,加入乙酸调pH至5,使用硅藻土抽滤,滤液减压浓缩后用乙酸乙酯(30mL)溶解,水洗,饱和食盐水洗,无水硫酸钠干燥,减压浓缩,柱层析(PE:EA=2:1),得到石胆酸(白色固体,860mg,产率91%)。mp:185-186.5℃.1H NMR(500MHz,DMSO-d6)δ11.93(s,1H),4.42(d,J=3.6Hz,1H),3.41-3.33(m,1H),2.27-2.18(m,1H),2.14-2.05(m,1H),1.92(d,J=10.8Hz,1H),1.83-1.74(m,2H),1.71-1.64(m,2H),1.62-1.57(m,1H),1.56-1.46(m,2H),1.39-1.29(m,7H),1.25-1.12(m,6H),1.11-1.00(m,4H),0.94-0.88(m,1H),0.87(t,J=3.1Hz,6H),0.61(s,3H).13C NMR(125MHz,DMSO-d6)δ175.28,70.32,56.51,56.01,42.73,42.01,40.44,40.15,36.74,35.85,35.62,35.30,34.66,31.18,31.14,30.83,28.18,27.37,26.63,24.31,23.73,20.89,18.58,12.32.HRMS(ESI):calcd for C24H40NaO4[M+Na]+,399.2870,found399.2885.(3-2) Compound 3 (1.0g, 2.51mmol), 20mL isopropanol, sodium tert-butoxide (482mg, 5.02mmol) and 1.0g Raney Ni were successively added to the autoclave, and H 2 was replaced and pressurized to 4.0MPa, react at 90°C for 24h. After TLC detected that the reaction of the raw materials was complete, acetic acid was added to adjust the pH to 5, suction filtration was performed using celite, the filtrate was concentrated under reduced pressure, dissolved in ethyl acetate (30 mL), washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure , column chromatography (PE:EA=2:1) to obtain lithocholic acid (white solid, 860 mg, yield 91%). mp: 185-186.5°C. 1 H NMR (500MHz, DMSO-d 6 ) δ 11.93(s, 1H), 4.42(d, J=3.6Hz, 1H), 3.41-3.33(m, 1H), 2.27- 2.18(m, 1H), 2.14-2.05(m, 1H), 1.92(d, J=10.8Hz, 1H), 1.83-1.74(m, 2H), 1.71-1.64(m, 2H), 1.62-1.57( m,1H),1.56-1.46(m,2H),1.39-1.29(m,7H),1.25-1.12(m,6H),1.11-1.00(m,4H),0.94-0.88(m,1H), 0.87(t, J=3.1Hz, 6H), 0.61(s, 3H). 13 C NMR (125MHz, DMSO-d 6 )δ175.28, 70.32, 56.51, 56.01, 42.73, 42.01, 40.44, 40.15, 36.74, 35.85,35.62,35.30,34.66,31.18,31.14,30.83,28.18,27.37,26.63,24.31,23.73,20.89,18.58,12.32.HRMS(ESI):calcd for C 24 H 40 NaO 4 [M+Na] + , 399.2870,found399.2885.
本发明的保护内容不局限于以上实施例。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点都被包括在本发明中,并且以所附的权利要求书为保护范围。The protection content of the present invention is not limited to the above embodiments. Variations and advantages that can occur to those skilled in the art without departing from the spirit and scope of the inventive concept are included in the present invention, and the appended claims are the scope of protection.
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010578080.4A CN111560045A (en) | 2020-06-23 | 2020-06-23 | Method for synthesizing lithocholic acid by taking BA as raw material |
CN202011415144.5A CN112625079A (en) | 2020-06-23 | 2020-12-07 | Method for synthesizing lithocholic acid by taking BA as raw material |
PCT/CN2021/071035 WO2021258723A1 (en) | 2020-06-23 | 2021-01-11 | Method for synthesizing lithocholic acid with ba as raw material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010578080.4A CN111560045A (en) | 2020-06-23 | 2020-06-23 | Method for synthesizing lithocholic acid by taking BA as raw material |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111560045A true CN111560045A (en) | 2020-08-21 |
Family
ID=72069457
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010578080.4A Withdrawn CN111560045A (en) | 2020-06-23 | 2020-06-23 | Method for synthesizing lithocholic acid by taking BA as raw material |
CN202011415144.5A Pending CN112625079A (en) | 2020-06-23 | 2020-12-07 | Method for synthesizing lithocholic acid by taking BA as raw material |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011415144.5A Pending CN112625079A (en) | 2020-06-23 | 2020-12-07 | Method for synthesizing lithocholic acid by taking BA as raw material |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN111560045A (en) |
WO (1) | WO2021258723A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112375117A (en) * | 2020-11-14 | 2021-02-19 | 湖南科瑞生物制药股份有限公司 | Preparation method of lithocholic acid and intermediate thereof |
WO2021258723A1 (en) * | 2020-06-23 | 2021-12-30 | 江苏佳尔科药业集团股份有限公司 | Method for synthesizing lithocholic acid with ba as raw material |
CN113943336A (en) * | 2021-04-09 | 2022-01-18 | 华东师范大学 | Method for synthesizing cholesterol by taking BA as raw material |
CN114524856A (en) * | 2022-01-27 | 2022-05-24 | 华东师范大学 | Synthetic method of high-purity plant source cholesterol |
WO2023179721A1 (en) * | 2022-03-25 | 2023-09-28 | 苏州恩泰新材料科技有限公司 | 7-ketolithocholic acid intermediate, synthesis method therefor, and application thereof |
CN117801044A (en) * | 2024-02-29 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | Continuous production method and device for progesterone |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113461764A (en) * | 2021-06-22 | 2021-10-01 | 北京泛球生物科技有限公司 | Synthetic method of ursodeoxycholic acid |
WO2023081166A1 (en) * | 2021-11-02 | 2023-05-11 | Sandhill One, Llc | Stereoselective steroidal reductions |
CN115286675B (en) * | 2022-08-30 | 2024-02-27 | 湖北共同生物科技有限公司 | Preparation method of progesterone intermediate |
CN115536719B (en) * | 2022-09-16 | 2024-02-09 | 江苏佳尔科药业集团股份有限公司 | A method for synthesizing high-purity plant-derived 7-ketolithocholic acid |
CN115466300B (en) * | 2022-10-18 | 2024-10-22 | 湖南科瑞生物制药股份有限公司 | A bile acid intermediate A7 and its synthesis method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1385867B1 (en) * | 2001-05-02 | 2006-08-30 | Novo Nordisk A/S | Preparation of bile acids |
GB201608776D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
CN106046093A (en) * | 2016-05-30 | 2016-10-26 | 华东师范大学 | Synthesizing method of lithocholic acid |
AU2017345399B2 (en) * | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
CN106977572B (en) * | 2017-06-01 | 2019-05-03 | 江苏佳尔科药业集团有限公司 | A method of using hyodesoxycholic acid as Material synthesis lithocholic acid |
CN107011404B (en) * | 2017-06-01 | 2019-05-03 | 江苏佳尔科药业集团有限公司 | A method of using cholic acid as Material synthesis lithocholic acid |
CN109021052B (en) * | 2018-03-15 | 2021-04-06 | 山东睿鹰制药集团有限公司 | Method for synthesizing lithocholic acid by taking androstenedione as raw material |
CN111072744B (en) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | Method for synthesizing ursodeoxycholic acid by taking BA as raw material |
CN111560045A (en) * | 2020-06-23 | 2020-08-21 | 江苏佳尔科药业集团股份有限公司 | Method for synthesizing lithocholic acid by taking BA as raw material |
CN112375117A (en) * | 2020-11-14 | 2021-02-19 | 湖南科瑞生物制药股份有限公司 | Preparation method of lithocholic acid and intermediate thereof |
-
2020
- 2020-06-23 CN CN202010578080.4A patent/CN111560045A/en not_active Withdrawn
- 2020-12-07 CN CN202011415144.5A patent/CN112625079A/en active Pending
-
2021
- 2021-01-11 WO PCT/CN2021/071035 patent/WO2021258723A1/en active Application Filing
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021258723A1 (en) * | 2020-06-23 | 2021-12-30 | 江苏佳尔科药业集团股份有限公司 | Method for synthesizing lithocholic acid with ba as raw material |
CN112375117A (en) * | 2020-11-14 | 2021-02-19 | 湖南科瑞生物制药股份有限公司 | Preparation method of lithocholic acid and intermediate thereof |
CN113943336A (en) * | 2021-04-09 | 2022-01-18 | 华东师范大学 | Method for synthesizing cholesterol by taking BA as raw material |
CN113943336B (en) * | 2021-04-09 | 2024-06-18 | 华东师范大学 | Method for synthesizing cholesterol by taking BA as raw material |
CN114524856A (en) * | 2022-01-27 | 2022-05-24 | 华东师范大学 | Synthetic method of high-purity plant source cholesterol |
CN114524856B (en) * | 2022-01-27 | 2024-03-15 | 华东师范大学 | Synthesis method of high-purity plant-derived cholesterol |
WO2023179721A1 (en) * | 2022-03-25 | 2023-09-28 | 苏州恩泰新材料科技有限公司 | 7-ketolithocholic acid intermediate, synthesis method therefor, and application thereof |
CN117801044A (en) * | 2024-02-29 | 2024-04-02 | 天津凯莱英医药科技发展有限公司 | Continuous production method and device for progesterone |
Also Published As
Publication number | Publication date |
---|---|
WO2021258723A1 (en) | 2021-12-30 |
CN112625079A (en) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111560045A (en) | Method for synthesizing lithocholic acid by taking BA as raw material | |
CN113943336B (en) | Method for synthesizing cholesterol by taking BA as raw material | |
CN106046093A (en) | Synthesizing method of lithocholic acid | |
CN115884978A (en) | Process for preparing cholic acid derivatives and starting materials therefor | |
KR20240135777A (en) | Method for synthesizing high-purity plant-derived cholesterol | |
CN114874277A (en) | Synthesis method of cholesterol | |
KR20240135778A (en) | Synthesis method of high purity cholesterol | |
CN114920698B (en) | Preparation method of 6-chloro-2-methyl-2H-indol-5-amine | |
WO2022228080A1 (en) | Method for synthesizing 7-ketone-based cholic acid by using ba as raw material | |
CN107353264B (en) | Batch synthesis method of dihydrogibberellin | |
RU2709493C1 (en) | Method of producing roxadustat | |
CN103980120A (en) | Synthesis method of D,L-danshensu isopropyl ester | |
CN105153013B (en) | The synthetic method of the ketone of 6 bromine isoindoline 1 | |
KR20100028543A (en) | Process for preparing aromatase inhibitors | |
CN106554254A (en) | A kind of synthetic method of 2,3 ', 4,5 ' tetrahydroxy bibenzyl of natural product | |
US6090952A (en) | (2R, 3S, 22R, 23R)-2,3,22,23-tetrahydroxy-24-ethyl-β-homo-7-oxa-5α-cholesta n-6-one and a process for preparing the same | |
CN112479967A (en) | Biliverdin compound and preparation method and application thereof | |
CN107200729B (en) | Preparation method of 4- (2-methoxyphenyl) -5- (2-pyridyl) -3-aminoisoxazole | |
CN111100042A (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
CN115594692B (en) | A method for preparing an anti-influenza virus drug intermediate | |
CN1308085A (en) | Preparation process of deoxycholeic acid of bear | |
CN117659109B (en) | Synthesis of Trenbolone | |
CN108863899B (en) | A kind of synthetic method of indolin-2-one compound and its application | |
CN117088830B (en) | Synthesis method of 2-amino-2- (furan-3-yl) acetic acid compound | |
CN115246833B (en) | Preparation method of Olatinib compound and intermediate compound thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200821 |
|
WW01 | Invention patent application withdrawn after publication |